Free Newsletter
Bristol inks $2.4B deal for Medarex
Free newsletter via e-mail
Tools
Bristol-Myers Squibb agreed to buy Medarex for about $2.4 billion to double its pipeline of experimental biological drugs, including one nearing U.S. approval for skin cancer. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: